Anika Therapeutics | ANIK - Despesas De Vendas E Administração

Preço das Ações
14.76
Mudança Diária
-0.46 -3.02%
Mensal
2.79%
Anual
8.21%
Q2 Previsão
14.36




Despesas De Vendas E Administração Alterar Data
Abbott USD 3.13B 125M 2025-12
Agenus USD 10.56M 13.04M 2025-12
Agios Pharmaceuticals USD 42.97M 1.7M 2025-12
Anika Therapeutics USD 10.01M 14K 2025-12
Arrowhead Research USD 46.02M 8.84M 2025-12
Enanta Pharmaceuticals USD -1.05 0.31 2024-12
Halozyme Therapeutics USD 64.64M 27.11M 2025-12
Heron Therapeutics USD 23.74M 605K 2025-12
Insmed USD 212.48M 26.11M 2025-12
Integra LifeSciences USD 156.45M 12.6M 2025-12
Intrexon USD 10.31M 41K 2024-06
J&J USD 6.75B 831M 2025-12
Karyopharm Therapeutics USD 9.56M 17.63M 2025-12
Ligand Pharmaceuticals USD 28.45M 8.27M 2025-09
MacroGenics USD 7.94M 1.96M 2025-12
Merit Medical Systems USD 114.83M 7.45M 2025-12
Rigel Pharmaceuticals USD 27.04M 1M 2024-09
Sangamo BioSciences USD 9.64M 1.83M 2024-06
Sanofi EUR 2.75B 455M 2025-12
Smith & Nephew USD 1.42B 65M 2025-12
Stryker USD 2.14B 150M 2025-12
Surmodics USD 11.4M 3.18M 2025-06
Veracyte USD 43.31M 8.43M 2025-12
Xencor USD 17.04M 70.74M 2025-12
Zimmer Biomet Holdings USD 855.7M 44.3M 2025-12